Page 2 of 3
123

2023 (6 POSTS)

Henderson RG, Lefever TW, Heintz MM, Trexler KR, Borghoff SJ, Bonn-Miller MO. 2023. Oral toxicity evaluation of cannabidiol. Food Chem Toxicol 176(June):113786; doi: 10.1016/j.fct.2023.113778. PMID: 37105391.

View Abstract

Rogers JM, Heintz MM, Thompson CM, Haws LC. 2023. A putative adverse outcome network for neonatal mortality and lower birth weight in rodents: Applicability to per- and polyfluoroalkyl substances and relevance to human health. Birth Defects Res 115(11)1011-1062; doi: 10.1002/bdr2.2185. PMID: 37219003.

View Abstract

Klaren WD, Heintz MM, East AW, Thompson CM, Haws LC. In vitro transcriptomic analyses informing the mode of action of HFPO-DA (GenX) in the liver. Poster presented at Society of Toxicology Annual Meeting, Nashville, TN, March 2023.

Thompson CM, Heintz MM, Wolf JC, Cheru R, Haws LC, Cullen JM. 2023. Assessment of mouse liver histopathology following exposure to HFPO-DA with emphasis on understanding mechanisms of hepatocellular death. Toxicol Pathol 51(1–2):4–14; doi: 10.1177/01926233231159078. PMID: 36987989.

View Abstract

Heintz MM, Haws LC, Klaunig JE, Cullen JM, Thompson CM. 2023. Assessment of the mode of action underlying development of liver lesions in mice following oral exposure to HFPO-DA and relevance to humans. Toxicol Sci 192(1):15–29; doi: 10.1093/toxic/kfad004. PMID: 36629480.

View Abstract

2022 (4 POSTS)

LaPlaca SB, Heintz MM, Wikoff D, Haws LC. Multi-step integration of ecotoxicological study reliability in ecological risk assessment. Poster at Society of Environmental Toxicology and Chemistry SETAC North America 43rd Annual Meeting, Philadelphia, PA, November 2022.

View Abstract

Heintz MM, Chappell GA, Thompson CM, Haws LC. 2022. Evaluation of transcriptomic responses in livers of mice exposed to the short-chain PFAS compound HFPO-DA. Front Toxicol 4(Jun 27):937168; doi: 10.3389/ftox.2022.937168. PMID: 35832492.

View Abstract

Rogers JM, Heintz MM, Thompson CM, Haws LC. Development of a putative adverse outcome pathway for neonatal mortality in rodents: Implications for human health risk assessments of PFAS. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

View Abstract

Heintz MM, Chappell GA, Thompson CM, Wolf JC, Rogers JM, Haws LC. HFPO-DA (GenX) transcriptomic responses in pregnant and non-pregnant rat livers: Analyses to inform the role of maternal effects on neonatal toxicity. Poster presented at Society of Toxicology 61st Annual Meeting, San Diego, CA, March 2022.

View Abstract

2021 (5 POSTS)

Thompson CM, Aardema MJ, Heintz MM, MacGregor JT, Young RR. 2021. A review of mammalian in vivo genotoxicity of hexavalent chromium: Implications for oral carcinogenicity risk assessment. Crit Rev Toxicol 51(10)820-849; doi: 10.1080/10408444.2021.2000934. PMID: 35060824.

View Abstract

Heintz MM, Doepker CL, Wikoff DS, Hawks SE. 2021. Assessing the food safety risk of ochratoxin A in coffee: A toxicology-based approach to food safety planning. J Food Sci 86(11):4799-4810; doi: 10.1111/1750-3841.15938.

View Abstract

Doepker CD, Heintz MM, van de Ligt JLG, Wikoff DS. 2021. Review of potential risks associated with supplementary dietary exposure to nitrate-containing compounds in swine — A paradox in light of emerging benefits. Trans Anim Sci 5(4):txab203; doi: 10.1093/tas/txab203. PMID: 34909600.

View Abstract

Chappell GA, Heintz MM, Borghoff SJ, Doepker CL, Wikoff DS. 2021. Lack of potential carcinogenicity for steviol glycosides — Systematic evaluation and integration of mechanistic data into the totality of evidence. Food Chem Toxicol 150(April):112045; doi: 10.1016/j.fct.2021.112045. PMID: 33587976.

View Abstract

Chappell GA, Heintz MM, Haws LC. 2021. Transcriptomic analyses of livers from mice exposed to 1,4-dioxane for up to 90 days to assess potential mode(s) of action underlying liver tumor development. Curr Res Toxicol 2:30–41; doi: 10.1016/j.crtox.2021.01.003.

View Abstract

2020 (3 POSTS)

Heintz MM, McRee, R, Kumar, R, Baldwin, WS. 2020. Gender differences in diet-induced steatotic disease in Cyp2b-null mice. PLoS ONE 15(3):e0229896; doi: 10.1371/journal.pone.0229896.

View Abstract

Heintz MM, Olack EM, Baldwin WS. Human CYP2B6 is an anti-obesity enzyme that produces active α-linolenic acid metabolites. Society of Toxicology 59th Annual Meeting, Virtual, March 2020.

View Abstract

Heintz MM, McRee R, Kumar R, Baldwin WS. Gender differences in diet-induced nonalcoholic steatohepatitis (NASH) in Cyp2b-null mice. Society of Toxicology 59th Annual Meeting, Virtual, March 2020.

View Abstract

2019 (5 POSTS)

Heintz MM, Kumar R, Rutledge M, Baldwin WS. 2019. Cyp2b-null male mice are susceptible to diet-induced obesity and perturbations in lipid homeostasis. J Nutr Biochem 70(August):125–137; doi: 10.1016/j.jnutbio.2019.05.004.

View Abstract

Heintz MM, Kumar R, Baldwin WS. Cyp2b-null male mice are susceptible to high-fat diet-induced obesity due to changes in PUFA metabolism and response to hepatic lipids as measured by RNAseq. International Congress on Toxicology (ICTXV), Honolulu, HI, July 2019.

Olack E, Heintz MM, Baldwin WS. Human CYP2B6 is an anti-obesity enzyme involved in unsaturated fatty acid metabolism. International Congress on Toxicology (ICTXV), Honolulu, HI, July 2019.

Page 2 of 3
123